Research To Practice | Oncology Videos

Latest Episodes:

Ovarian Cancer | Meet The Professor: Optimizing the Management of Ovarian Cancer — Part 3 of a 4-Part Series Jan 24, 2024

Show notes

Featuring perspectives from Dr Antonio González-Martín, including the following topics:

Introduction: Treatment-Related Second Cancers (0:00)
Case: A woman in her mid 40s (gBRCA) who presents with ascites and is diagnosed with high-grade serous ovarian cancer (HGSOC) with extensive peritoneal disease — Lyndsay J Willmott, MD (12:37)
Case: A woman in her early 40s (gBRCA1) with HGSOC who experienced cardiac arrest due to anaphylaxis during paclitaxel infusion as part of a neoadjuvant paclitaxel/carboplatin/bevacizumab regimen — Kellie E Schneider, MD (30:33)
Case: A woman in her late 50s (gBRCA1) with HGSOC and pelvic node recurrence after perioperative paclitaxel/carboplatin and optimal interval debulking surgery — Karim ElSahwi, MD (39:45)
Case: A woman in her late 50s (gBRCA1) with Stage IIIA ovarian cancer and elevated creatinine due to donor nephrectomy — Paul DiSilvestro, MD (43:05)
Case: A woman in her early 60s with recurrent ovarian cancer after a chemotherapy and niraparib maintenance regimen and tumor treating fields with paclitaxel on a clinical trial — Gigi Chen, MD (46:28)
Case: A woman in her late 50s with gBRCA1 and PMH of breast cancer and prophylactic bilateral salpingo-oophorectomy who develops recurrent peritoneal cancer and responds for 10 months to olaparib followed by chemotherapy followed by rucaparib and nivolumab on the TAPUR trial — John K Chan, MD (51:52)
Journal Club (55:30)

CME information and select publications

Acute Myeloid Leukemia and Myelodysplastic Syndromes | Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series Jan 17, 2024

Show notes

Featuring perspectives from Dr Richard M Stone, including the following topics: • Introduction: ASH 2023 Update — Key Oral Presentations (0:00) • Case: A woman in her early 90s with dementia who presented with anemia and was diagnosed with low-risk myelodysplastic syndromes (MDS) with ring sideroblasts, now receiving luspatercept — Eric H Lee, MD, PhD (9:09) • Case: An African American woman in her early 60s with high-risk del(5q) MDS who receives oral decitabine/cedazuridine — Henna Malik, MD (26:05) • Case: A man in his late 60s with therapy-related acute myeloid leukemia (AML) with a FLT3-ITD mutation — Rebecca L Olin, MD, MSCE (34:49) • Case: A woman in her early 70s with PMH of inflammatory breast cancer diagnosed with FLT3-ITD AML who achieved a complete response (CR) with azacitidine/venetoclax, followed by gilteritinib maintenance for 2 years — Zanetta S Lamar, MD (40:43) • Case: A man in his mid 30s who presents with pathologic spinal fracture, is diagnosed with myeloid sarcoma and receives induction CLAG-M with CR followed by consolidation high-dose cytarabine — Anna Halpern, MD (43:56) • Case: A man in his mid 80s with MDS, complex cytogenetics and a TP53 mutation treated with azacitidine/venetoclax — Neil Morganstein, MD (46:40) • Case: A woman in her early 70s with newly diagnosed, poor-risk AML, ineligible for intensive chemotherapy (ECOG PS 2) who receives a hypomethylating agent/venetoclax — Amany R Keruakous, MD, MS (49:56) • Case: A man in his early 70s with relapsed AML (SRSF2, IDH1, ASXL1 mutations) after azacitidine/venetoclax, now receiving ivosidenib — Dr Halpern (55:23) CME information and select publications

Multiple Myeloma | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Multiple Myeloma Jan 10, 2024

Show notes

Featuring perspectives from Dr Amrita Krishnan, Dr Sagar Lonial, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, including the following topics: • Introduction (0:00) • Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Richardson (4:47) • Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM — Dr Lonial (30:01) • Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM — Dr Raje (57:22) • Bispecific Antibodies in the Treatment of MM — Dr Krishnan (1:19:54) • Other Novel Agents and Strategies Under Investigation for MM — Dr Orlowski (1:37:56) CME information and select publications

Diffuse Large B-Cell Lymphoma | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Diffuse Large B-Cell Lymphoma Jan 08, 2024

Show notes

Featuring perspectives from Prof Michael Dickinson, Prof Grzegorz S Nowakowski, Prof Gilles Salles, Dr Laurie H Sehn and Dr Jason Westin, including the following topics: • Introduction (0:00) • Up-Front Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Salles (6:58) • Promising Investigational Approaches to First-Line Therapy for DLBCL — Dr Nowakowski (25:27) • Selection and Sequencing of Novel Therapies for Relapsed/Refractory (R/R) DLBCL — Dr Sehn (48:08) • Incorporation of CAR T-Cell Therapy into the Management of R/R DLBCL — Dr Westin (1:18:15) • Role of Bispecific Antibodies in the Treatment of DLBCL — Prof Dickinson (1:43:27) CME information and select publications

HER2-Low Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast Cancer Jan 04, 2024

Show notes

Featuring perspectives from Dr Aditya Bardia, Dr Lisa A Carey, Dr Shanu Modi and Prof Peter Schmid, including the following topics: • Introduction (0:00) • Optimal Approaches to HER2 Testing for the Identification of HER2-Low Breast Cancer — Dr Carey (3:27) • Available Data with and Current Role of HER2-Targeted Therapy for HER2-Low Disease — Dr Modi (22:41) • Identification and Management of Toxicities with Trastuzumab Deruxtecan — Prof Schmid (48:20) • Future Directions in the Management of HER2-Low Breast Cancer — Dr Bardia (1:10:18)

CME information and select publications

Chronic Lymphocytic Leukemia | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Chronic Lymphocytic Leukemia Jan 03, 2024

Show notes

Featuring perspectives from Dr Farrukh T Awan, Dr Matthew S Davids, Dr Stephen J Schuster, Dr William G Wierda and Dr Jennifer Woyach, including the following topics: • Introduction (0:00) • Front-Line Treatment for Chronic Lymphocytic Leukemia (CLL) — Dr Wierda (6:02) • Novel Strategies Combining Bruton Tyrosine Kinase (BTK) and Bcl-2 Inhibitors in the Treatment of CLL — Dr Davids (32:37) • Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Awan (53:35) • Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Woyach (1:15:49) • Promising Investigational Agents and Strategies — Dr Schuster (1:37:53)

CME information and select publications

HER2-Negative Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Localized HER2-Negative Breast Cancer Dec 28, 2023

Show notes

Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:

Introduction (0:00)
Role of Genomic Assays in Treatment Decision-Making for Localized ER-Positive, HER2-Negative Breast Cancer — Dr Goetz (6:03)
Integration of Ovarian Function Suppression into the Management of Breast Cancer in Premenopausal Patients — Dr Burstein (33:34)
Role of CDK4/6 Inhibitors and Other Novel Agents in Therapy for ER-Positive Localized Breast Cancer — Dr Hurvitz (52:35)
Optimizing the Use of Neoadjuvant and Adjuvant Therapy for Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:16:18)
Emerging Role of Circulating Tumor DNA Evaluation in the Management of Breast Cancer — Dr Pusztai (1:42:03)

CME information and select publications

Follicular, Mantle Cell and Hodgkin Lymphoma | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Follicular, Mantle Cell and Hodgkin Lymphoma Dec 27, 2023

Show notes

Featuring perspectives from Dr Jeremy S Abramson, Dr Stephen M Ansell, Dr Nancy L Bartlett, Dr Jonathon B Cohen, Dr Jonathan W Friedberg and Dr Brad S Kahl, including the following topics:

Introduction (0:00)
Evolving Role of Novel Treatment Strategies in Follicular Lymphoma (FL) — Dr Friedberg (7:20)
Integration of CAR (Chimeric Antigen Receptor) T-Cell Therapies and Bispecific Antibodies into the Management of FL — Dr Abramson (33:08)
Up-Front Treatment for Mantle Cell Lymphoma (MCL) — Dr Kahl (58:54)
Therapeutic Sequencing for Patients with Relapsed/Refractory (R/R) MCL — Dr Cohen (1:23:46)
First-Line Treatment Strategies for Hodgkin Lymphoma (HL) — Dr Bartlett (1:45:42)
Current and Future Management of R/R HL — Dr Ansell (2:18:49)

CME information and select publications

ER-Positive Metastatic Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of ER-Positive Metastatic Breast Cancer Dec 21, 2023

Show notes

Featuring perspectives from Prof Francois-Clement Bidard, Dr Erika Hamilton, Dr Komal Jhaveri, Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:

Introduction (0:00)
Optimal Integration of CDK4/6 Inhibitors into the Management of ER-Positive Metastatic Breast Cancer (mBC) — Dr Kaklamani (7:00)
Novel Strategies to Overcome Resistance to Endocrine Therapy — Dr Jhaveri (26:20)
Current Role of Antibody-Drug Conjugates in the Management of ER-Positive mBC — Dr Rugo (1:00:09)
Current and Future Role of Selective Estrogen Receptor Degraders (SERDs) in the Management of ER-Positive mBC — Prof Bidard (1:28:59)
Novel Therapies Under Investigation for Patients with ER-Positive mBC — Dr Hamilton (1:40:50)
CME information and select publications

Gynecologic Cancers | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gynecologic Cancers — Part 1 of a Special 3-Part Edition Dec 20, 2023

Show notes

Featuring an interview with Dr David M O'Malley, including the following topics:

Prevalence of HER2 positivity among various gynecologic cancer subtypes; current testing recommendations (0:00)
Trastuzumab and other HER2-targeted therapies as a component of treatment for HER2-positive gynecologic cancers (15:17)
Key efficacy outcomes achieved with trastuzumab deruxtecan (T-DXd) among patients with advanced ovarian, endometrial and cervical cancers in the DESTINY-PanTumor02 study (18:05)
Incidence of interstitial lung disease (ILD) and other toxicities with T-DXd in the DESTINY-PanTumor02 trial; strategies to manage ILD associated with HER2-directed antibody-drug conjugates (27:59)
Case: A woman in her mid-60s with HER2-low (IHC 1+) recurrent uterine carcinosarcoma receives T-DXd on a clinical trial (34:26)
Case: A woman in her mid-70s with recurrent uterine serous cancer and history of Crohn's disease (51:05)
Case: A woman in her mid-60s with Stage IIIC primary uterine serous cancer receives carboplatin/paclitaxel/trastuzumab followed by maintenance trastuzumab with no evidence of disease 4 years later (56:50)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected